# Spironolactone Improved Children With Gene Mutations Related to NCOR

> **NCT06678685** · PHASE2,PHASE3 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 2 (estimated)

## Conditions studied

- NCOR Gene Mutations
- Spironolactone
- ASD

## Interventions

- **DRUG:** .spironolactone

## Key facts

- **NCT ID:** NCT06678685
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06678685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06678685, "Spironolactone Improved Children With Gene Mutations Related to NCOR". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06678685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*